Aerpio Pharmaceuticals – Innovation Showcase at Ophthalmology Innovation Summit @ AAO 2019

Aerpio’s Kevin Peters, MD, discusses how his company’s lead VE-PTP inhibitor/Tie2 activator AKB-9778 enhances both vascular stability and fluid outflow, making it a potential candidate for glaucoma.

Kevin Peters, MD, Chief Scientific Officer & Chief Medical Officer speaks for Aerpio Pharmaceuticals during the Innovative Showcase at OIS@AAO 2019.

REGISTER for our next ophthalmology conference today.